Lytix Biopharma AS

DB:6BG Stock Report

Market Cap: €25.9m

Lytix Biopharma Management

Management criteria checks 3/4

Lytix Biopharma's CEO is Oystein Rekdal, appointed in Jan 2003, has a tenure of 21.75 years. total yearly compensation is NOK4.77M, comprised of 72.7% salary and 27.3% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth €73.09K. The average tenure of the management team and the board of directors is 5.5 years and 3.3 years respectively.

Key information

Oystein Rekdal

Chief executive officer

NOK 4.8m

Total compensation

CEO salary percentage72.7%
CEO tenure21.8yrs
CEO ownership0.3%
Management average tenure5.5yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Oystein Rekdal's remuneration changed compared to Lytix Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-NOK 76m

Mar 31 2024n/an/a

-NOK 86m

Dec 31 2023NOK 5mNOK 3m

-NOK 88m

Sep 30 2023n/an/a

-NOK 99m

Jun 30 2023n/an/a

-NOK 91m

Mar 31 2023n/an/a

-NOK 61m

Dec 31 2022NOK 4mNOK 4m

-NOK 56m

Sep 30 2022n/an/a

-NOK 43m

Jun 30 2022n/an/a

-NOK 51m

Mar 31 2022n/an/a

-NOK 63m

Dec 31 2021NOK 8mNOK 7m

-NOK 48m

Sep 30 2021n/an/a

-NOK 44m

Jun 30 2021n/an/a

-NOK 40m

Mar 31 2021n/an/a

-NOK 35m

Dec 31 2020NOK 7mNOK 4m

-NOK 42m

Dec 31 2019NOK 2mNOK 2m

-NOK 33m

Dec 31 2018NOK 2mNOK 2m

-NOK 62m

Dec 31 2017NOK 2mNOK 2m

-NOK 69m

Compensation vs Market: Oystein's total compensation ($USD438.20K) is about average for companies of similar size in the German market ($USD486.19K).

Compensation vs Earnings: Oystein's compensation has increased whilst the company is unprofitable.

CEO

Oystein Rekdal

21.8yrs

Tenure

NOK 4,765,000

Compensation

Dr. Oystein Rekdal, Ph.D. co-founded Lytix Biopharma AS in 2003 and serves as its Chief Executive Officer since September 11, 2019. Dr. Rekdal was Chief Scientific Officer of Lytix Biopharma AS since April...

Leadership Team

NamePositionTenureCompensationOwnership
Oystein Rekdal
Co-Founder & CEO21.8yrsNOK 4.77m0.28%
€ 73.1k
Gjest Breistein
Chief Financial Officer6.1yrsno data0.022%
€ 5.8k
Gry Stensrud
Chief Technology Officer3.6yrsno data0.010%
€ 2.6k
Baldur Sveinbjørnsson
Chief Scientific Officer4.8yrsno data0.0086%
€ 2.2k
Ole Nordby
Head of IR & Communication Managerno datano datano data
Jacqueline Earabino
Head of Clinical Operationsno datano datano data

5.5yrs

Average Tenure

Experienced Management: 6BG's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kjetil Hestdal
Non-Executive Independent Director3.3yrsNOK 331.00kno data
James Allison
Member of Scientific Advisory Board5.3yrsno datano data
Brynjar Forbergskog
Non-Executive Independent Director3.3yrsNOK 331.00kno data
Jayson Rieger
Non-Executive Independent Director3.3yrsNOK 331.00kno data
Marie Roskrow
Chairperson1.5yrsNOK 91.00kno data
Padmanee Sharma
Member of Scientific Advisory Board5.3yrsno datano data
Marie-Louise Fjallskog
Director3.3yrsNOK 331.00kno data
Aurelien Marabelle
Member of Scientific Advisory Boardno datano datano data
Robert H.I. Andtbacka
Member of Scientific Advisory Boardno datano datano data
Sandra Demaria
Member of Scientific Advisory Boardno datano datano data
Evelina Vagesjo
Non-Executive Independent Director3.3yrsNOK 331.00kno data

3.3yrs

Average Tenure

62yo

Average Age

Experienced Board: 6BG's board of directors are considered experienced (3.3 years average tenure).